For its second fiscal quarter (ending June 30), Catalyst Pharmaceutical Inc (NASDAQ: CPRX) has reported a -3% decline in E.P.S. from $0.36 a year ago to $0.35 in the current quarter. This performance was $-0.08 short of the consensus estimate of $0.43. E.P.S. were $0.59 for the latest four quarters through June 30 versus $1.10 for the same period a year ago — a decline of -46%.
Recent Price Action
On 8/7/24, Catalyst Pharmaceutical Inc (NASDAQ: CPRX) stock rose slightly by 0.2%, closing at $16.23. Trading volume in this advance was normal. Relative to the market the stock has been strong over the last nine months but has declined -5.5% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, CPRX is expected to continue to be a major Value Builder.
Catalyst Pharmaceutical has a current Value Trend Rating of A (Highest Rating). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Catalyst Pharmaceutical has a neutral Power Rating of 58 but a very high Appreciation Score of 90, triggering the Highest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of A. This review will be completed in the next several days.
Be the first to comment